KA2237, our dual-selective PI3K-p110β/δ inhibitor, has been under investigation in a Phase I clinical trial for patients with B-cell lymphoma. Of the 13 subjects receiving a dose of KA2237 in the therapeutic window, 3 subjects gained a partial response and 4 achieved complete remission. The toxicity profile of KA2237 is favourable. The study is now closed to recruitment.
The Phase I clinical trials has been conducted at The University of Texas MD Anderson Cancer Center, as part of our strategic collaboration.